Hematological Disorders

'Groundbreaking' Technology Heals Serious Injuries with a Single Touch

By August 09, 2017

"By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining," said Dr. Chandan Sen.

Angioedema Risk Assessed for Aliskiren vs. Other Antihypertensives

By August 07, 2017

The case-control analysis found no significant difference in the angioedema risk for aliskiren monotherapy and fixed-dose combination compared to BBs with adjusted odds ratio of 0.99 (95% CI, 0.45-2.20) and 1.06 (0.40-2.76), respectively.

Caplacizumab Fast-Tracked for Acquired Thrombotic Thrombocytopenic Purpura

By July 26, 2017

The Phase 2 TITAN study (n=75) evaluated the safety and efficacy of caplacizumab with standard of care of plasma exchange and immunosuppression.

Angioedema Risk Evaluated for Levetiracetam Versus Phenytoin

By July 25, 2017

"The results suggest that levetiracetam has the same or lower risk for angioedema than phenytoin," wrote the researchers.

Haegarda Available for Routine Prophylaxis of Hereditary Angioedema Attacks

By July 25, 2017

Haegarda reduced the number of HAE attacks by a median of 95% vs. placebo

Idarucizumab Effective for Dabigatran Reversal in Emergency Situations

July 13, 2017

Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery

Eculizumab Linked to High Risk of Meningococcal Disease, Despite Vaccination

By July 10, 2017

In vitro data have shown that eculizumab impairs meningococcal killing in whole blood despite patients being vaccinated against the appropriate serogroup. The current vaccines against meningococcal disease only target serogroup-specific proteins and do not provide protection against nongroupable N. meningitidis.

FDA Approves New Sickle Cell Disease Treatment

By July 07, 2017

The safety and efficacy of Endari were evaluated in a randomized clinical trial involving patients aged 5-58 years with sickle cell disease who had ≥2 painful crises within 12 months prior to trial enrollment.

Breckenridge Approved for Generic Vidaza

By June 29, 2017

Vidaza is indicated as treatment for myelodysplastic syndrome (MDS), specifically refractory anemias and chronic myelomonocytic leukemia; it can be given either subcutaneously (SC) or intravenously (IV).

Emicizumab Beneficial in Hemophilia A Patients With Inhibitors to FVIII

By June 29, 2017

The primary analysis of the study arm showed a statistically and clinically significant reduction in bleeding by 87% (risk rate [RR] 0.13; P<0.0001] with emicizumab prophylaxis.

New FDA Policy Aims to Increase Number of Generics on Market

By June 29, 2017

"No patient should be priced out of the medicines they need, and as an agency dedicated to promoting public health, we must do our part to help patients get access to the treatments they require," said FDA Commissioner Scott Gottlieb, MD.

New Treatment Option for Hereditary Angioedema FDA-Approved

By June 23, 2017

The human plasma-derived, purified, pasteurized, lyophilized concentrate is derived from large pools of human plasma from U.S. donors.

NDA Filed for Tavalisse for Immune Thrombocytopenia Treatment

By June 19, 2017

Tavalisse is an oral treatment designed to inhibit SYK kinase, a key signaling member in the immune process that leads to platelet destruction in ITP.

PPIs May Benefit Older Patients on Antiplatelet Therapy

June 15, 2017

Research suggests proton-pump inhibitors should be co-prescribed in patients age 75 years

Ferrous Sulfate vs. Iron Polysaccharide in Iron-Deficient Anemic Infants

June 14, 2017

The researchers found that the mean hemoglobin increased from 7.9 to 11.9 g/dL in the ferrous sulfate group, compared with 7.7 to 11.1 g/dL in the iron polysaccharide complex group (greater difference of 1.0 g/dL with ferrous sulfate).

Dosing Errors Common with Certain Blood-Thinning Medications

June 06, 2017

Study of newer medications finds 16 percent receive too much or too little

Anticoagulation During Pregnancy Linked to Distinct Maternal, Fetal Risks

June 02, 2017

VKA, LMWH tied to lowest risk of adverse maternal, fetal outcomes, respectively

Rebinyn Approved to Treat Hemophilia B

By June 01, 2017

Rebinyn, a recombinant DNA-derived coagulation Factor IX concentrate, temporarily replaces the missing coagulation Factor IX in hemophilia B patients.

Icatibant Evaluated for ACE Inhibitor-Induced Angioedema

By May 30, 2017

Upper airway angioedema, while rare, is a potentially life-threatening side effect of ACEIs.

Mepolizumab Evaluated in Eosinophilic Vasculitis

May 26, 2017

The researchers found that, compared with placebo, mepolizumab treatment correlated with significantly more accrued weeks of remission.

FDA Committee Votes in Favor of Endari for Sickle Cell Disease

By May 25, 2017

An efficacy study of L-glutamine (Study 09-01) showed that the treatment resulted in a lower frequency of sickle cell painful crises, longer time to first and second crisis compared to placebo.

New Formulation of Jadenu Approved

By May 22, 2017

Both the tablets and granules should not be taken with aluminum-containing antacid products. The drug labeling contains additional information for patients who are on current chelation therapy with Exjade (deferasirox) tablets for oral suspension and converting to Jadenu.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

By May 18, 2017

Wechsler, ME et al. "Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis". DOI: 10.1056/NEJMOA1702079

Novel Hemophilia A Gene Therapy Gets Fast Track Status

By May 16, 2017

The Food and Drug Administration (FDA) has granted Fast Track designation to SB-525 (Sangamo Therapeutics) for the treatment of hemophilia A.

Delaying Anticoagulation Tx in Afib May Increase Dementia Risk

May 15, 2017

Even patients with a low risk of stroke could benefit, researchers say

Antithyroid Drug Induces Rare, Dangerous Side Effect

By May 11, 2017

"Periodic screening and monitoring of CBC while on treatment is crucial to monitor development of neutropenia which can be totally asymptomatic," the authors concluded.

Use of Guideline-Recommended Tx Low in PAD Patients

May 03, 2017

Increased odds of antiplatelet therapy, statins, ACEI/ARB, smoking counseling with comorbid CAD

Blood Type May be Factor in Heart Attack Risk

By May 02, 2017

The odds ratio for all coronary events and combined cardiovascular events was found to be significantly higher in carriers of a non-O blood group.

FDA to Review Fostamatinib for Chronic, Persistent ITP

By April 18, 2017

Rigel announced its submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenic purpura (ITP).

Emicizumab Evaluated in Children with Hemophilia A

By April 17, 2017

The interim results from HAVEN 2, after a median of 12 weeks of treatment, showed that prophylaxis with emicizumab is associated with clinically meaningful reduction in the number of bleeds over time.